225 related articles for article (PubMed ID: 34461985)
21. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
22. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
23. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
[TBL] [Abstract][Full Text] [Related]
24. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
[TBL] [Abstract][Full Text] [Related]
25. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
Jung SH; Kim YJ; Yim SH; Kim HJ; Kwon YR; Hur EH; Goo BK; Choi YS; Lee SH; Chung YJ; Lee JH
Oncotarget; 2016 Aug; 7(34):55264-55275. PubMed ID: 27419369
[TBL] [Abstract][Full Text] [Related]
27. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
28. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.
Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
[TBL] [Abstract][Full Text] [Related]
29. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
30. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
31. Expression of Normal or Mutated X-Linked
El Ayachi I; Zou XY; Yan X; Lou Y; Huang GT
J Dent Res; 2020 Feb; 99(2):196-203. PubMed ID: 31775564
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
33. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
35. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
36.
Abuhadra N; Mukherjee S; Al-Issa K; Adema V; Hirsch CM; Advani A; Przychodzen B; Makhoul A; Awada H; Maciejewski JP; Sekeres MA; Nazha A
Leuk Lymphoma; 2019 Jun; 60(6):1587-1590. PubMed ID: 30618304
[No Abstract] [Full Text] [Related]
37. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ; Zeidan AM
Expert Rev Hematol; 2015 Apr; 8(2):155-8. PubMed ID: 25697572
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
39. [Mutation analysis of 77 patients with normal-karyotype myelodysplastic syndrome].
Qin W; Chen M; Cai X; Chao H; Liu J; Jiang N; Zhou M; Lu X; Chen S; Zhang R; He C; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Sep; 36(9):857-861. PubMed ID: 31515775
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
